Business overview
About us
TISSUE REGENIX GROUP is a pioneering, international medical technology company, focusing on the development of regenerative products utilising our two platform technologies, dCELL®, addressing soft tissue needs, and BioRinseTM, providing sterile bone allografts.
We are currently helping to transform the treatment of patients in key surgical applications: BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology, and Cardiac.
Our Vision
To establish TRG as a leader in the science and innovation of regenerative medicine.
Transforming patient care and delivering favourable health economic outcomes.
Group snapshot: progress in 2021
- $19.7m revenue FY2021
- $7.7m cash at 31 December 2021
- Distribution via strategic partners, direct specialist sales and distribution partners
Product portfolio
High growth product lines focused on bone, skin (dermis) and birth tissue:
Bone
BioRinse®
Flagship Products
ConCelltrate®
Applications
- Spine
- Foot/ankle
- Dental
- Orthopaedics
Differentiators
- Induces new bone growth
- Faster healing
- Superior handling
- Reduced flush out
Soft Tissue
dCELL®
Flagship Products
DermaPure®
Applications
- Urogynaecology
- Sports medicine
- Open wound
- Plastics
Differentiators
- Clinical outcomes
- No second graft site required
- Stored at room temperature
- Superior handling
Birth Tissue
Proprietary
Flagship Products
AmnioWorks™
Applications
- Ophthalmology
- Wound covering
Differentiators
- Clinical outcomes
- Barrier can provide faster healing
- Stored at room temperature
Global Operations Infrastructure
Platform for international expansion
Current locations
Tissue Regenix, Leeds, UK
Cellright Technologies, San Antonio, Texas
GBM-V, Rostock, Germany
Our values
Dedication to patients
Passion for innovation
Drive for excellence
Uncompromising integrity
You may also be interested in